A prospective cohort study of real-world clinical diagnosis and treatment of metabolic related fatty liver disease (MAFLD)

Hubei Provincial Hospital of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Diagnostic criteria
•The diagnosis of MAFLD[1] is based on hepatic steatosis (detected by liver histology, imaging, or non-invasive biomarkers) and the presence of at least one of the following three criteria, including:
•(1) Overweight or obese;
•(2) Type 2 diabetes (T2DM);
•(3) There are at least two risk factors for abnormal metabolism:
•a. Waist circumference: Asian men = 90cm, women = 80cm
•b. Blood pressure: =130/85mmHg or receive specific drug treatment
•c. Triglyceride: =1.7mmol/L or receive specific drug treatment
•d. High-density lipoprotein cholesterol: male <1.0 female <1.3mmol/L or receiving specific drug treatment
•e. Pre-diabetes: fasting blood glucose 5.6~6.9mmol/L or postprandial blood glucose 7.8~11.0mmol/L or glycosylated hemoglobin 5.7~6.4%
•f. Homeostasis Model Assessment - Insulin Resistance Index: HOMA-IR=2.5
•g. Blood high-sensitivity C-reactive protein: CRP>2mg/L
•2. Inclusion criteria
•1) Age: 10-65 years old, gender is not limited;
•2) Meet the above diagnostic criteria for metabolic-associated fatty liver disease (MAFLD);
•3) Good compliance, willing to abide by the principle of follow-up;
•4) Agree to sign the informed consent;
•5) Only those who meet all the above conditions can participate in this study.

•Exclusion criteria
•1) Serious diseases of the heart, liver, lung, kidney, brain, blood, neuropsychiatric system, etc., whose disease is not under control;
•2) Diagnose patients with liver fibrosis, liver cirrhosis, alcoholic liver disease, immune liver disease and drug-induced liver disease;
•3) Patients with various malignant tumors;
•4) Patients who have received fatty liver related diagnosis and treatment within 1 month;
•5) Pregnant or lactating women;
•6) The researcher believes that it is not suitable to participate in this research;
•Anyone who meets any of the above criteria cannot participate in this study.

发起方